This drug candidate is showing real promise. Let’s take a closer look
The post Neuroscientific Biopharmaceuticals (ASX:NSB) share price surges 11% on drug update appeared first on The Motley Fool Australia. –
Shares in the company are trading at 34 cents at the time of writing, up 11.48%.
Let’s take a look at what may be weighing on investors’ minds today.
What did the company announce?
The Neuroscientific Biopharmaceuticals share price is on the rise following promising results from a safety assessment of the company’s lead drug candidate, EmtinB.
In research conducted in vitro, the EmtinB drug did not cause any adverse reactions or toxicity. The trial involved screening 173 potential biological targets known to stimulate drug-induced reactions in humans.
Neuroscientific is a biotechnology company working on peptide-based drugs to treat neurodegenerative diseases.
EmtinB binds to specific proteins known as receptors to activate signalling pathways between the cells. This can help to protect and regenerate the nervous system.
The in vitro trials were carried out by research company Eurofins at laboratories in France. This screen is recommended to reduce risk before progressing to human trials.
The completion of this safety assessment is seen by the company as a major step towards conducting phase I trials in humans.
Speaking on the results fuelling the Neuroscientific Biopharmaceuticals share price, chief executive officer and managing director Matt Liddelow said:
These positive safety results add further confidence to existing safety data for EmtinB in demonstrating it’s low likelihood to cause any major safety issues in humans — and is another major step towards achieving the landmark milestone of starting first-in-human Phase I studies in the first half of 2022.
I look forward to updating the market with further progress in the New Year as we advance towards Phase I clinical studies.
Neuroscientific Biopharmaceuticals share price snap shot
The Neuroscientific Biopharmaceuticals share price has gained 36% since the start of the year. For perspective, the S&P/ASX 200 Index (ASX: XJO) has returned more than 12% over the same period.
Despite this, the company’s shares have lost 7% in the past month but are up around 8% this week.
The company has a market capitalisation of roughly $43.7 million based on its current share price.
The post Neuroscientific Biopharmaceuticals (ASX:NSB) share price surges 11% on drug update appeared first on The Motley Fool Australia.
Should you invest $1,000 in Neuroscientific Biopharmaceuticals right now?
Before you consider Neuroscientific Biopharmaceuticals, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Neuroscientific Biopharmaceuticals wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.